Journal article Open Access

Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency

Gropman, Andrea

Citation Style Language JSON Export

  "DOI": "10.1002/ana.10626", 
  "author": [
      "family": "Gropman, Andrea"
  "issued": {
    "date-parts": [
  "abstract": "Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare disorder characterized by an inborn error of the catabolism of the inhibitory neurotransmitter GABA. Because of the deficiency of SSADH, the final enzyme of the GABA degradation pathway, the substrate, succinic semialdehyde, is shunted towards production of 4\u2010hydroxybutyric acid (\u03b3\u2010hydroxybutyric acid). Elevations of \u03b3\u2010hydroxybutyric acid can be detected in the physiologic fluids of patients with SSADH deficiency, and forms the mainstay of diagnosis. The clinical features of SSADH deficiency include nonspecific neurologic manifestations such as mental retardation/developmental delay, absent speech, hypotonia, nonprogressive ataxia, features of autism or pervasive developmental delay, developmental language delay (dyspraxia, receptive, and expressive delays), and occasionally, seizures. Although the metabolic pathway has been established, it is not known whether insufficient GABA and/or excess \u03b3\u2010hydroxybutyric acid contribute to the disease phenotype. Pharmacological therapy in patients with this disorder has been limited to vigabatrin, an anticonvulsant that blocks GABA transaminase. This review will discuss therapeutic options in SSADH deficiency, on the basis of patient experience, and preliminary work using a murine model. Finally, a discussion of adjunctive therapies will be included. Ann Neurol 2003;54 (suppl 6):S66\u2013S72", 
  "title": "Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency", 
  "type": "article-journal", 
  "id": "1229117"
Views 279
Downloads 245
Data volume 24.2 MB
Unique views 276
Unique downloads 241


Cite as